The death of U.S. Supreme Court Justice Antonin Scalia leaves a number of healthcare-related cases in limbo. The news also quickly sparked a debate over who would replace him amid the presidential campaign.
Providers are pushing hard to have Kentucky throw out a long-standing policy that limits reimbursement for desperately needed chronic-care visits for Medicaid beneficiaries.
Elizabeth Dudek, secretary of Florida's Agency for Health Care Administration, called the deficiencies at Calhoun Liberty Hospital “so egregious” that the Blountstown hospital will be fined and required to submit a plan of correction by Feb. 19.
Partners HealthCare in Boston reported a small loss on its health plan during the first quarter of the fiscal year. Overall, the system had a positive operating margin, but that margin fell sharply from a year ago as labor and other costs grew faster than revenue.
Kaiser Permanente made strong gains in California's Affordable Care Act insurance exchange last year, contributing to a surge in new members and strong revenue growth.
Health insurers that sold plans on the exchanges in 2015 and enrolled droves of high-cost members could haul away as much as $7.7 billion this year, as part of the healthcare law's reinsurance program.
It's become clear that even if you have health insurance in the U.S., you're still susceptible to receiving pricey medical bills—many of which can be a complete surprise. The federal government wants that to end.
DaVita Healthcare Partners' core business of delivering kidney care once again carried the company's earnings, while its newer medical group division continued to struggle. And more legal trouble could be on the horizon for the Denver-based company.
In a Democratic primary debate Thursday night, Hillary Clinton said the numbers in Vermont Sen. Bernie Sanders' single-payer healthcare plan don't add up, and reiterated her call for Democrats to rally around protecting and improving the Affordable Care Act.
The U.S. Food and Drug Administration ceased clinical trials for a CTI BioPharma cancer drug this week after several participants died from the drug's side effects.